David Bredt - 31 Dec 2025 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Role
Chief Scientific Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
RAPP
Transactions as of
31 Dec 2025
Net transactions value
-$197,338
Form type
4
Filing time
05 Jan 2026, 16:20:05 UTC
Previous filing
16 Dec 2025
Next filing
16 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bredt David Chief Scientific Officer RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON /s/ Troy Ignelzi, Attorney-in-Fact 05 Jan 2026 0002022087

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RAPP Common Stock Award -18,000 -4.2% 410,642 31 Dec 2025 Direct F1
transaction RAPP Common Stock Sale $197,338 -6,567 -1.6% $30.05 404,075 31 Dec 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 4, 2024, the Reporting Person was granted performance-based restricted stock units ("PSUs") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025.
F2 Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.04 to $30.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.